Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Merger or Acquisition (November 2026)
8 slides from Mayne Pharma's merger presentation, Nov 6, 2026
Slide 1: Divestment of Mayne Pharma International
rsonal use only Mayne Pharma Group Limited Divestment of Mayne Pharma International Aaron Gray (CEO) Griffin Buchanan (CFO) 6 November 2026
Slide 2: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market rsonal use only disclosures. This material is not intended to be relied upon as advice to investors or
Slide 3: Transaction Highlights
Transaction Highlights1 Sale of MPI completes Mayne Pharma’s transition to a specialty pharmaceutical company 100% focused on the United States rsonal use only $55.5m 0.79x 12.1x Total cash consideration FY26 MPI revenue FY26 MPI direct contribution at completion of $70.7m of $4.6m 3Q FY27 100% $122
Slide 4: Strategic Rationale
Strategic Rationale A defining step in Mayne Pharma’s transformation rsonal use only 100% focus on the United States • All management attention and capital directed to US Women’s Health and Dermatology/DistributeRx, the Company’s highest-return opportunities • Single-market focus to accelerate execu
Slide 5: Mayne Pharma International at a Glance
Mayne Pharma International at a Glance Salisbury Manufacturing Australian Commercial CDMO & Export rsonal use only • Australian rights to NEXTSTELLIS®, PBS listed • Contract development and manufacturing for • Manufacturing, packaging and development from 1 October 2025 third-party customers facilit
Slide 6: Conditions Precedent and Timetable
Conditions Precedent and Timetable • Regulatory rsonal use only • Notification to, and a determination permitting completion by, the Australian Competition and Consumer Commission (ACCC) under the mandatory merger notification regime in Part IVA of the Competition and Consumer Act 2010 (Cth) • The T
Slide 7: Mayne Pharma Post-Transaction: 100% US Focus
Mayne Pharma Post-Transaction: 100% US Focus Women’s Health Dermatology Corporate rsonal use only • Drive market penetration – increase low • Scale disintermediation – specialty • Balance sheet strength – a debt-light balance single digit market share + solid market pharmacy ecosystem to reduce fric
Slide 8: Q&A
Q&A rsonal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Click here to view this Presentation on Investor Hub This presentation has been approved for release by the Chair of Mayne Pharma You deserve tomorrow. 8
Mayne Pharma Group — Merger or Acquisition (November 2026) on 6ix